1. Home
  2. APM

as of 04-30-2026 3:38pm EST

$0.88
$0.02
-1.69%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Founded: 2010 Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 7.3M IPO Year: 2018
Target Price: N/A AVG Volume (30 days): 24.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.65 - $4.47 Next Earning Date: 03-31-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: